QRG Capital Management Inc. Sells 626 Shares of Humana Inc. (NYSE:HUM)

QRG Capital Management Inc. lessened its holdings in Humana Inc. (NYSE:HUM) by 22.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,144 shares of the insurance provider’s stock after selling 626 shares during the period. QRG Capital Management Inc.’s holdings in Humana were worth $544,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in HUM. Pinnacle Wealth Management Advisory Group LLC raised its position in shares of Humana by 3.6% in the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock valued at $272,000 after purchasing an additional 37 shares during the period. Atlas Brown Inc. grew its stake in Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after buying an additional 38 shares during the last quarter. Moors & Cabot Inc. raised its holdings in Humana by 2.5% in the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after acquiring an additional 40 shares during the period. Mather Group LLC. lifted its position in Humana by 21.0% during the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock worth $60,000 after acquiring an additional 41 shares during the last quarter. Finally, Capital Advisors Ltd. LLC boosted its holdings in shares of Humana by 26.1% during the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider’s stock worth $53,000 after acquiring an additional 43 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Up 0.8 %

HUM opened at $263.74 on Wednesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company’s 50 day moving average price is $271.40 and its two-hundred day moving average price is $285.08. The firm has a market capitalization of $31.82 billion, a price-to-earnings ratio of 26.51, a PEG ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM) last issued its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. Humana’s dividend payout ratio (DPR) is 35.58%.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.32% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Morgan Stanley lowered their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. StockNews.com lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday. JPMorgan Chase & Co. dropped their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Truist Financial raised their target price on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Finally, Piper Sandler upped their price target on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Twenty analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.